Publications by authors named "Karin Tyroller"

Claim this Profile
A
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
Joaquim Bellmunt, Thomas Powles, Se Hoon Park, Eric Voog, Begona P Valderrama, Karin Tyroller

Eur Urol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.
Petros Grivas, Jeanny B Aragon-Ching, Joaquim Bellmunt, Yohann Loriot, Miguel A Climent Duran, Karin Tyroller

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab first-line maintenance in advanced urothelial carcinoma: Complete screening for prognostic and predictive factors using machine learning in the JAVELIN Bladder 100 phase 3 trial.
Juliane Manitz, Aslihan Gerhold-Ay, Pascal Kieslich, Parantu Shah, Thomas Mrowiec, Karin Tyroller

Cancer Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
Jean Hoffman-Censits, Petros Grivas, Thomas Powles, Jessica Hawley, Karin Tyroller

Future Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer.
Yi-Long Wu, Keunchil Park, Ross A Soo, Yan Sun, Karin Tyroller

BMC Cancer· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis